Clinical Trial Search

Phase 3 N=1,651 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

Primary: Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) — 26.3; 31.7 Percentage…

Novartis Pharmaceuticals Results Oct 2018 28.1% serious AE View details

Phase 3 N=335 Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Pulmonary Arterial Hypertension

Primary: Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT) — 16; 11; 25; 11 Items

Actelion Results Oct 2018 17.3% serious AE View details

Phase 3 N=60 Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Congenital Bleeding Disorder · Haemophilia A

Primary: Incidence Rate of Factor VIII Inhibitors (Above or Equal to 0.6 BU (Bethesda Units)/mL) for the Main Phase of the Trial — 43.1 Percentage of participants

Novo Nordisk A/S Results Oct 2018 60.0% serious AE View details

Phase 3 N=12 Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Primary: Part A: Pre-dose Concentration (Ctrough) of LUM and IVA — 8710; 12300; 94.0; 216 nanogram per milliliter (ng/mL)

Vertex Pharmaceuticals Incorporated Results Oct 2018 5.6% serious AE View details

Phase 3 N=67 Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Fabry Disease

Primary: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide…

Amicus Therapeutics Results Oct 2018 11.8% serious AE View details

Phase 3 N=493 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

Breast Cancer

Primary: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus…

Mylan Inc. Results Oct 2018 38.1% serious AE View details

Phase 3 N=394 A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Follicular Lymphoma

Primary: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 — 70.7; 75.5 percentage of participants

Pfizer Results Oct 2018 8.1% serious AE View details

Phase 3 N=125 Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Sleep Disorders

Primary: Total Sleep Time (TST) — 51.03; 18.71 minutes — p==0.035

Neurim Pharmaceuticals Ltd. Results Oct 2018 3.2% serious AE View details

Phase 3 N=182 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

Male Hypogonadism

Primary: Absolute Change From Baseline in T Cholesterol — 0.2; 8.2 mg/dL

Clarus Therapeutics, Inc. Results Oct 2018 6.6% serious AE View details

Phase 3 N=452 Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

Tetanus · Acellular Pertussis · Diphtheria

Primary: Number of Seroprotected Subjects Against Diphtheria (Anti-D) and Tetanus (Anti-T) — 204; 211; 204; 211 Subjects

GlaxoSmithKline Results Oct 2018 7.1% serious AE View details

Phase 3 N=972 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Primary: Number of Participants With Adverse Events (AEs) — 950; 780; 516 Participants

Hoffmann-La Roche Results Oct 2018 59.6% serious AE View details

Phase 3 N=617 Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Schizophrenia

Primary: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. — -14.3; -20.2; -23.0; -21.2 Units on a Scale…

Forest Laboratories Results Oct 2018 2.8% serious AE View details

Phase 3 N=354 Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

Schizophrenia

Primary: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score — -15.367…

Indivior Inc. Results Oct 2018 0.6% serious AE View details

Phase 3 N=74 Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Primary: Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 63.3; 20.0; 71.4…

Tanabe Pharma Corporation Results Oct 2018 16.2% serious AE View details

Phase 3 N=452 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Primary: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review — 14.7; 9.2 months — p=<0.0001

Pfizer Results Oct 2018 27.3% serious AE View details